Hope For Patients of Gastric Cancer And Pancreatic Cancer – CT041 Typical Cases and Achievements
🔬✨Hope For Patients of Gastric And Pancreatic Cancer – CT041 Typical Cases and Achievements ✨🔬
Patient 1: 53-year-old Male
Gastric Cancer,
Pancreatic Cancer
Advanced gastric cancer with liver, lung, bone metastases, and multiple lymph nodes and peritoneal metastases. Previously treated with 2 systemic therapies including PD-1 antibodies, CLDN18.2 expression 60% (3+). After CAR-T therapy, tumor size decreased by nearly 50%, achieving sustained remission for 32 weeks.
Patient 2: 57-year-old Female
Gastric Cancer,
Pancreatic Cancer
Gastric cancer with peritoneal metastasis and Sister Mary Joseph’s nodule (malignant tumor metastasis forming a nodule-like lesion in the umbilicus). Previously received third-line therapy including PD-1 antibodies, CLDN18.2 expression 80% (2+). Achieved partial remission after CAR-T therapy, with sustained response exceeding 56 weeks.
🏆 CT041 Achievements 🏆
– In May 2020, FDA approved CT041 for investigational new drug (IND) authorization for the treatment of claudin18.2-positive gastric, gastroesophageal junction, or pancreatic adenocarcinoma patients.
– In 2020, received orphan drug designation from the U.S. FDA for the treatment of gastric/gastroesophageal junction cancer.
– In 2021, granted orphan drug designation by the European Medicines Agency (EMA) and qualified for the European PRIME program.
– In 2022, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA.
– On March 3, 2022, approved by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) to enter Phase II clinical trials!
We are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!
we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!
You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:
doctor.huang@globecancer.com,
or WhatsApp+8613717959070
The Medical Department will contact you as soon as they receive the reports.
#CancerResearch #Immunotherapy #CART #MedicalBreakthrough #ClinicalTrials #FDAApproval #OrphanDrug #HealthcareInnovation #GastricCancer #PancreaticCancer #CT041 #MedicalAdvancement #RegenerativeMedicine #RMAT #EMAApproval #NMPAApproval #MedicalScience #PrecisionMedicine #PatientCare